

Two Thromboxane A₂ Receptor Isoforms in Human Platelets

Opposite Coupling to Adenylyl Cyclase with Different Sensitivity to Arg⁶⁰ to Leu Mutation

Takako Hirata,*[‡] Fumitaka Ushikubi,[‡] Akira Kakizuka,[‡] Minoru Okuma,* and Shuh Narumiya[‡]

*The 1st Division, Department of Internal Medicine and [‡]Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto 606-01, Japan

Abstract

Thromboxane A₂ (TXA₂) receptor is a key molecule in hemostasis as its abnormality leads to bleeding disorders. Two isoforms of the human TXA₂ receptor have been cloned; one from placenta and the other from endothelium, here referred to as TXR α and TXR β , respectively. These isoforms differ only in their carboxyl-terminal tails. We report that both isoforms are present in human platelets. The two isoforms expressed in cultured cells show similar ligand binding characteristics and phospholipase C (PLC) activation but oppositely regulate adenylyl cyclase activity; TXR α activates adenylyl cyclase, while TXR β inhibits it. The Arg⁶⁰ to Leu mutant of TXR α , which has been shown to impair PLC activation (Hirata, T., A. Kakizuka, F. Ushikubi, I. Fuse, M. Okuma, and S. Narumiya. 1994. *J. Clin. Invest.* 94: 1662–1667), also impairs adenylyl cyclase stimulation, whereas that of TXR β retains its activity to inhibit adenylyl cyclase. These findings suggest that the pathway linked to adenylyl cyclase inhibition might be involved in some of the TXA₂-induced platelet responses such as shape change and phospholipase A₂ activation which remain unaffected in the patients with this mutation. (*J. Clin. Invest.* 1996. 97:949–956.) Key words: G-proteins • phospholipase C • phospholipases A • platelet activation • alternative splicing

Introduction

Platelet activation is a complex network of interdependent biochemical processes through which platelets undergo a sequence of responses: shape change, aggregation, and secretion. All of these responses can be induced by a number of physiological agonists such as thrombin, ADP, platelet-activating factor and thromboxane A₂ (TXA₂)¹ (1). TXA₂ is a major arachidonic acid metabolite in platelets that binds to the specific membrane receptor to initiate these processes (2). The TXA₂ receptor is linked via a guanine nucleotide-binding protein (G protein) of the G_q class to phospholipase C (PLC), which hydrolyses phosphoinositides to the two potent stimulatory second messengers inositol 1,4,5-triphosphate (IP₃) and diacylglycerol (3, 4). These molecules affect divergent pathways of

platelet activation; IP₃ causes increases in cytoplasmic free calcium and diacylglycerol causes activation of protein kinase C. However, whether this pathway contributes to all of the TXA₂-induced platelet responses remains undefined. Some studies using the radiolabeled TXA₂ analogs as ligands demonstrated two classes of binding sites in platelets, and indicated that they might represent the receptor subtypes (5–8). They further suggested that the two putative subtypes of the receptor may independently mediate shape change and aggregation (8, 9). This suggestion has been supported by the reports that platelet shape change and aggregation can be differentiated by several TXA₂ analogs. For example, in some species, the TXA₂ agonist U46619 induces platelet shape change and an increase in calcium without aggregation (10). In addition, the TXA₂ analog S-145 prevents aggregation and secretion by U46619 but itself induces shape change (11). One model consistent with these observations is that the TXA₂ receptor-mediated signaling consists of two separate receptor-effector systems mediating distinct functional responses; one linked to PLC activation resulting in platelet aggregation and secretion, and the other mediating an increase in cytosolic calcium and platelet shape change (12).

We have recently identified Arg⁶⁰ to Leu mutation in the first cytoplasmic loop of the TXA₂ receptor in a bleeding disorder characterized by defective platelet aggregation responses to TXA₂ and its analogs (13). The platelets of the patients with this mutation were impaired in PLC activation. Consistently, the Arg⁶⁰ to Leu mutant of TXR α expressed in cultured cells exhibited impaired agonist-induced PLC activation. Their platelets, however, exhibited shape change and phospholipase A₂ (PLA₂) activation when stimulated by a TXA₂ agonist (14, 15). These findings favor the hypothesis that shape change and PLA₂ activation are not mediated by PLC activation but by other pathways independent of PLC activation and not affected by this mutation. A cDNA encoding a TXA₂ receptor has initially been cloned from human placenta and the deduced 343-amino acid sequence indicates that it belongs to the superfamily of G protein-coupled receptors (16). Recently, a cDNA encoding a receptor isoform of 407 amino acids has been isolated from human endothelium (17). These

Address correspondence to Shuh Narumiya, M.D., Ph.D., Department of Pharmacology, Kyoto University Faculty of Medicine, Yoshida, Sakyo-ku, Kyoto 606-01, Japan. Phone: 81-75-753-4392; FAX: 81-75-753-4693; E-mail: snaru@four.med.kyoto-u.ac.jp

Received for publication 11 August 1995 and accepted in revised form 30 November 1995.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/96/02/0949/08 \$2.00

Volume 97, Number 4, February 1996, 949–956

1. *Abbreviations used in this paper:* CHO, Chinese hamster ovary; G protein, guanine nucleotide-binding protein; GR32191, [1R-[1 α (Z), 2 β , 3 β , 5 α]]-(+)-7-[5-[[[(1,1'-biphenyl)-4-yl]methoxy]-3-hydroxy-2-(1-piperidiny)]cyclopentyl]-4-heptenoic acid; HBS, Hepes-buffered saline; I-BOP, [1S-[1 α , 2 α (Z), 3 β (1E, 3S*), 4 α]]-7-[3-[3-hydroxy-4-[4-iodophenoxy]-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid; IP₃, inositol 1,4,5-triphosphate; PI, phosphatidylinositol; PLA₂, phospholipase A₂; PLC, phospholipase C; RT, reverse transcription; S-145, 5Z-7-(3-endo-phenylsulphonylamino)bicyclo[2.2.1]hept-2-*exo*-yl]heptenoic acid; STA₂, 9,11-epithio-11,12-methano-TXA₂; TXA₂, thromboxane A₂; U46619, 15S-hydroxy-11 α , 9 α (epoxymethano)prosta-5Z, 13E-dienoic acid.

two isoforms, here referred to as TXR α and TXR β , are generated by alternative splicing from a single gene and differ only in their carboxyl-terminal domains; the 15 amino acid sequence in the carboxyl end of TXR α is replaced by a 79-amino acid sequence in TXR β . The existence of multiple isoforms could account for the separate effector systems linked to the TXA₂ receptor, provided both isoforms are present in platelets and divergent in their signaling pathways.

Here we report the identification of two isoforms of the human TXA₂ receptor in platelets. The two isoforms expressed in cultured cells showed the same ligand binding characteristics and agonist-induced activation of PLC but distinct effects on adenylyl cyclase activity; TXR α activated adenylyl cyclase, while TXR β inhibited it. Since the patients with the Arg⁶⁰ to Leu mutation of the TXA₂ receptor showed some of the TXA₂-induced platelet responses, we have examined the effects of this mutation on these pathways to explore their possible involvement in those responses. We show that the Arg⁶⁰ to Leu mutation selectively impairs the pathways linked to PLC activation and to adenylyl cyclase stimulation but not that linked to adenylyl cyclase inhibition. It is, therefore, possible that the pathway linked to adenylyl cyclase inhibition is involved in the platelet responses remaining unaffected in these patients.

Methods

Materials. 9,11-epithio-11,12-methano-TXA₂ (STA₂) was a generous gift from Ono Pharmaceuticals Co. Ltd. (Osaka, Japan). 5Z-7-(3-endo-phenylsulphonylaminobicyclo[2.2.1]hept-2-*exo*-yl) heptenoic acid (S-145) and its tritium derivative [³H]S-145 were generous gifts from Shionogi Research Laboratories (Osaka, Japan). [1S-[1 α , 2 α (Z), 3 β (1E, 3S*), 4 α]-7-[3-[3-hydroxy-4-[4-iodophenoxy]-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (I-BOP) was obtained from Cayman Chemical Co. (Ann Arbor, MI). [1R-[1 α (Z), 2 β , 3 β , 5 α]]-(+)-7-[5-[[[1, 1'-biphenyl]-4-yl]methoxy]-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid (GR32191) was kindly supplied by Dr. R. A. Coleman (Glaxo Research Ltd., Ware, England). Myo-[2-³H]inositol (19.1 Ci/mmol) and cAMP [¹²⁵I] assay system were obtained from Amersham Corp. (Arlington Heights, IL), pertussis toxin from Funakoshi Co. Ltd. (Tokyo, Japan), forskolin from Sigma Chemical Co. (St. Louis, MO) and RO-20-1724 from Paesel (Frankfurt/M, Germany). All other materials were obtained from the sources as described previously (13).

Amplification of platelet mRNA. Total RNA was extracted from platelets by the acid guanidium-phenol-chloroform method (18). 1 μ g of total RNA was reverse-transcribed (RT) in a volume of 20 μ l as described previously (19). For a control, reactions were carried out under the same conditions without reverse transcriptase. 2 μ l of the reaction mixture was used for amplification by polymerase chain reaction (PCR) in a final volume of 20 μ l, containing 50 mM KCl, 10 mM Tris-HCl (pH 8.8), 1.5 mM MgCl₂, 0.1% Triton X-100, 10% dimethylsulfoxide, 0.25 mM dNTPs, 1 U Taq Polymerase (Wako Pure Chemical Industries Ltd., Osaka, Japan), and 20 pmol of each primer. After denaturation at 94°C for 2 min, 35 cycles (94°C for 1 min, 62°C for 1 min, 72°C for 1.5 min) were followed by a final elongation step for 3.5 min at 72°C. Primers used are based on the sequences of the TXA₂ receptor isolated from placenta (16). One pair of primers include TX30 (5'-CCGCATGGCCTCAGAGCGCTAC-3') corresponding to nucleotides (nt) 371-393, as numbered in the published sequence (16), and 3T4 (5'-GGGGTGCCCGGTTTCACAT-3'; nt 1884-1903). Other pairs include 7S1 (5'-CTGCTCATCTACTG-CGCGT-3'; nt 868-887) and 3T4, or 7S1 and 3T2 (5'-CAGGGTCAA-AGAGCATGCAA-3'; nt 1787-1806). PCR products were electrophoresed, excised, purified using GeneClean II (Bio 101 Inc., Vista,

CA), and blunt-end-ligated to pBluescript II SK+ (Stratagene, La Jolla, CA). Plasmid subclones were sequenced by the dideoxy chain termination method.

Genomic PCR. Genomic DNA was prepared from white blood cells of the patient T.T. (13) as described (20). A 1146 bp fragment that includes the portion encoding peptide- β was amplified by PCR, using primers 12 (5'-GTCCAGGCTGACAGCTCTCC-3') corresponding to intronic nt -29 to -10 upstream from the second coding exon (21) and 3T4. PCR was done as described in RT-PCR except that 0.1 μ g genomic DNA was used instead of RT reaction mixture as a template. PCR products were subcloned and sequenced.

Expression of wild-type and mutant TXA₂ receptor isoforms. For transient expression, cDNAs encoding the two isoforms were inserted into the pCMX expression vector under the control of the cytomegalovirus promoter (22) and COS-m6 were transfected in 15-cm dishes with 25 μ g of plasmid DNA by calcium phosphate precipitation (23). The cells were grown in DME with 10% fetal calf serum and harvested at 72 h after transfection for ligand binding assays or at 24 h to be trypsinized and plated in 6-well plates for phosphatidylinositol (PI) assay. For stable expression, cDNAs encoding the wild-type and mutant isoforms were inserted into the mammalian expression vector pEF-BOS (24) with a blasticidin S-resistance marker (Funakoshi Co. Ltd.) and introduced into Chinese hamster ovary (CHO) cells by the calcium phosphate method. Stable transformants were cloned by selection in the α -modified minimal essential medium containing 10% fetal calf serum and 15 ng/ml blasticidin S (Funakoshi Co. Ltd.).

Ligand binding studies. Transfected COS-m6 cells or CHO cells were cultured in 15 cm dishes to confluency and harvested as described previously (25). Cells were washed once and suspended at 1 \times 10⁷ cells/ml in a buffer containing 20 mM Hepes (pH 7.4), 140 mM NaCl, 5 mM KCl, 5 mM MgCl₂. Binding assays were performed essentially as described (26). Briefly, cells (100 μ l) were incubated in a total volume of 200 μ l at 30°C for 1 h. In the [³H]S-145 saturation experiments, nine different concentrations of the radioligand (0.125-32 nM) were used. In the displacement experiments, 1 nM of [³H]S-145 and different concentrations of the unlabeled competitors were employed. The reaction was terminated by the addition of 4 ml of ice-cold 10 mM Tris (pH 7.4) and immediate vacuum filtration through GF/C filters (Whatman International Ltd., Maidstone, England) followed by four additional 4-ml washes with the same buffer. The radioactivity on the filter was measured by scintillation counting. Non-specific binding was determined in the presence of a 1,000-fold excess of unlabeled S-145.

Measurement of PI hydrolysis. Transfected COS-m6 cells or CHO cells were cultured in 6-well plates to 90% confluency in the medium described above and then incubated for 20 h in inositol-free DME with 10% dialyzed fetal calf serum containing 1 μ Ci/ml myo-[2-³H]inositol. The cells were washed with Hepes-buffered saline (HBS) and preincubated with 10 mM LiCl in HBS at 37°C for 10 min. Then various concentrations of STA₂ were added to each medium. After 5 or 30 min incubation, the medium was removed and the reaction was terminated by 1 ml of 5% trichloroacetic acid. The generation of IP₃ or total inositol phosphate was measured as described (27).

cAMP assays. CHO cells stably expressing wild-type or mutant isoforms were cultured in 24-well plates and treated with or without 100 ng/ml pertussis toxin for 12 h. They were then washed once with HBS and preincubated for 10 min in HBS containing 0.1 mM RO-20-1724 at 37°C. Cells were then stimulated for 10 min with I-BOP at the indicated concentrations with or without 1 μ M forskolin. The reaction was terminated by the addition of an equal volume (0.5 ml) of 10% trichloroacetic acid. Quantification of cAMP was performed by a radioimmunoassay using an Amersham cAMP assay kit.

Results

Identification of two isoforms of the human TXA₂ receptor in platelets. cDNAs encoding two isoforms of the human TXA₂




Figure 1. PCR detection of the two isoforms of the human TXA₂ receptor in platelets. (A) Ethidium bromide staining of PCR products. Platelet RNA was used as a template after the incubation in the presence (+) or absence (-) of reverse transcriptase (RT). PCR products were analyzed on 2% agarose gels. Two bands are identified in each PCR reaction using primers TX30 and 3T4 (reaction 1), 7S1 and 3T4 (reaction 2), and 7S1 and 3T2 (reaction 3). The larger and the smaller bands in each reaction correspond to TXR α and TXR β mRNAs, respectively. (B) Schematic representation of the two isoforms of the TXA₂ receptor showing the primers used in PCR. Putative transmembrane domains I-VII are shown by closed boxes and different carboxyl-terminal tails by a hatched box (peptide- α) and a dotted box (peptide- β). Splicing sites are indicated by inverted triangles. The positions of primers in each cDNA and the expected sizes of PCR products are shown. (C) Amino acid sequences of peptide- α and peptide- β . Peptide- α and peptide- β contain 15 and 79 amino acids, respectively.

receptor have already been cloned (16, 17). These are schematically represented in Fig. 1 B. Comparison of two cDNAs revealed that TXR β has a deletion of a 659-bp sequence that comprises the distal portion of the cytoplasmic carboxyl tail and the following 3' untranslated region of TXR α . Deletion of this sequence results in another reading frame downstream in TXR β . Consequently, a 15 amino acid carboxyl-terminal sequence of TXR α (peptide- α) is replaced with a new 79 amino acid sequence (peptide- β) in the carboxyl end of TXR β (Fig. 1 C). Peptide- α contains four serine and threonine residues as potential phosphorylation sites, whereas peptide- β contains 14 residues. To determine whether the two receptor isoforms exist in human platelets, RT-PCR was carried out. Two fragments were amplified using a sense primer TX30 located in the third transmembrane domain and an antisense primer 3T4 in the 3' untranslated domain shared by the two isoforms (Fig. 1 A, lane 1). The amplification of these fragments depended strictly on cDNA synthesis, indicating that the fragments were derived from RNA and not from contaminated genomic DNA. Sequence analyses confirmed that the larger band corresponds to TXR α and the smaller band TXR β . Additional PCR reactions using different pairs of primers (7S1+3T4 and

7S1+3T2) each yielded two bands of the expected size (Fig. 1 A, lanes 2 and 3), further confirming the presence of the two isoforms in platelets.

Ligand binding characteristics of the two TXA₂ receptor isoforms. To investigate functional differences between the two isoforms, TXR α and TXR β were transiently expressed in COS-m6 cells or stably expressed in CHO cells. The two isoforms expressed in CHO cells displayed indistinguishable, high-affinity binding of the TXA₂ receptor antagonist [³H]S-145 with a K_d value of 2.1 nM for both TXR α and TXR β (Fig. 2 A). Scatchard analyses using [³H]S-145 revealed a single class of binding sites on both receptor isoforms. Similar results were obtained on transfected COS-m6 cells (data not shown). Because previous studies using I-BOP, a TXA₂ agonist, and GR32191, a TXA₂ antagonist, detected two classes of binding sites in platelets (8, 12), binding of these ligands to the two isoforms were studied by testing their abilities to displace specific [³H]S-145 binding. I-BOP displaced specific [³H]S-145 binding to the two isoforms similarly (Fig. 2 B). GR32191 also showed similar displacement for the two isoforms (Fig. 2 C). Furthermore, GR32191, which identified reversible and irreversible binding sites in platelets (12), bound only irreversibly to both




Figure 2. Ligand binding characteristics of the two TXA₂ receptor isoforms. (A) Scatchard analyses of TXRα (●) or TXRβ (○). Specific [³H]S-145 binding to CHO cells stably expressing TXRα or TXRβ was determined. TXRα exhibited an affinity for [³H]S-145 ($K_d = 2.1$ nM) which was comparable to that of TXRβ ($K_d = 2.1$ nM). Both cell lines expressed a similar number of receptors ($B_{max} = 246.8$ and 216.3 fmol / 1×10^6 cells for TXRα and TXRβ, respectively). Data shown are representative of three independent experiments, each performed in duplicate. (B and C) Displacement of specific [³H]S-145 binding to TXRα (●) or TXRβ (○) by I-BOP (B) and GR32191 (C). Both ligands displaced specific [³H]S-145 binding to CHO cells stably expressing TXRα or TXRβ similarly. Each curve is representative of three independent experiments, each performed in duplicate.

isoforms (data not shown). Thus, the two isoforms at least under the present experimental conditions do not correspond to the subtypes shown previously in platelets.

PLC activation by the two TXA₂ receptor isoforms. We next investigated whether the different carboxyl-terminal tails affect the PLC activation. Untransfected COS-m6 cells did not show any significant increase in inositol phosphate production to the TXA₂ agonist STA₂ (data not shown). Stimulation of cells expressing TXRα or TXRβ by STA₂ induced an increase in inositol phosphate production with almost the same concentration-response curves (Fig. 3). Since we had previously shown that the Arg⁶⁰ to Leu mutation of TXRα impairs its agonist-induced activation of PLC, we asked whether this mutation also affects PLC activation mediated by TXRβ. Stable transformants expressing a similar number of wild-type or mutant TXRβ were chosen for this experiment. Mutant TXRβ exhibited an unaltered binding affinity for [³H]S-145, compared to that of wild-type TXRβ (Fig. 4 A). When the two cell lines were examined for the activation of PLC, mutant TXRβ was found to be impaired in its ability to produce agonist-induced PI hydrolysis (Fig. 4 B). These results indicate that the mutation impairs PLC activation both in TXRα and TXRβ. Thus, the Arg⁶⁰ in the first cytoplasmic loop appears to be essential for PLC activation.

Activation and inhibition of adenylyl cyclase by the two TXA₂ receptor isoforms. Previous studies have shown possible involvement of the adenylyl cyclase pathway in TXA₂-mediated platelet responses, although the results are conflicting (28). Therefore, we examined effects of the difference of the carboxyl-terminal tail on adenylyl cyclase activation in cells expressing the two isoforms. As shown in Fig. 5, I-BOP increased the level of cAMP in cells expressing TXRα in a concentration-dependent fashion above 10 nM, while no increase was




Figure 3. STA₂-induced PLC activation in COS-m6 cells expressing the two TXA₂ receptor isoforms. COS-m6 cells transiently expressing TXRα (●) or TXRβ (○) were incubated with STA₂ for 30 min and total inositol phosphate production was measured. Both isoforms are expressed in a similar number (190.1 pmol and 145.7 pmol / 1×10^6 cells for TXRα and TXRβ, respectively). The data are presented as fold increases, where the values from the cells in the absence of STA₂ were chosen as the reference values. Data points are mean \pm SE from 3 replicate wells from a single experiment. Where not shown, an SE bar is smaller than the symbol. The results were independently confirmed in two additional experiments. The EC₅₀ values for activation through TXRα and TXRβ were 2.3 and 3.9 nM, respectively.




Figure 4. Functional properties of wild-type and mutant TXR β stably expressed in CHO cells. (A) Scatchard analyses of wild-type (○) and mutant (▲) TXR β . Wild-type and mutant TXR β exhibited similar affinities for [³H]S-145 ($K_d = 1.8$ nM for both wild-type and mutant TXR β). Both cell lines expressed a similar number of receptors ($B_{max} = 204.9$ and 212.2 fmol / 1×10^6 cells for wild-type and mutant TXR β , respectively). (B) STA₂-induced IP₃ accumulation in CHO cells expressing wild-type (○) and mutant (▲) TXR β . CHO cells were incubated with STA₂ for 5 min and IP₃ production was measured. Data points are mean \pm SE from three replicate wells from a single experiment. The results were independently confirmed in two additional experiments. The data are presented as fold increases, where the values from the cells in the absence of STA₂ were chosen as the reference values.

found in those expressing TXR β . We next examined whether the two isoforms can inhibit adenylyl cyclase. I-BOP inhibited the forskolin-induced cAMP generation in cells expressing TXR β but not in cells expressing TXR α (Fig. 6 A). This inhibition was sensitive to pertussis toxin treatment (Fig. 6 C), suggesting that it was mediated by the interaction of the receptor with G_i/G_o. Since pertussis toxin did not affect adenylyl cyclase stimulation by TXR α (data not shown), it seems that each isoform couples to a separate G protein in addition to a common G protein of the G_q class.

Effects of the Arg⁶⁰ to Leu mutation on adenylyl cyclase activity. The finding that the TXA₂ receptor mediates pathways other than that linked to PLC led us to examine the effect of the Arg⁶⁰ to Leu mutation on these pathways, since the patients with this mutation show some platelet responses such as shape change and PLA₂ activation despite the defective activation of PLC when stimulated by a TXA₂ agonist. Before ad-




Figure 5. Adenylyl cyclase stimulation by wild-type and mutant TXR α . CHO cells expressing TXR α (●), TXR β (○) or the Arg⁶⁰ to Leu mutant of TXR α (▲) were incubated with various concentrations of I-BOP and the cAMP contents in the cells were measured as described in Methods. Data points are mean \pm SE from 3 replicate wells from a single experiment. The results were independently confirmed in 2 additional experiments. The EC₅₀ value for activation through TXR α was 17 nM.

ressing this question, we examined the genomic sequence corresponding to peptide- β , that had not been analyzed in our previous study (13), by genomic PCR in one of the patients, and confirmed that it bears no mutation. The Arg⁶⁰ to Leu mutation, which had been shown to impair PLC activation by TXR α , also impaired adenylyl cyclase activation by this isoform (Fig. 5). In contrast, as shown in Fig. 6 B, the mutant TXR β was capable of inhibiting adenylyl cyclase above the I-BOP concentration of 1 pM. This inhibitory effect was also sensitive to pertussis toxin treatment (Fig. 6 C). Taken together, the Arg⁶⁰ to Leu mutation affects the pathways linked to PLC activation and to adenylyl cyclase stimulation but not that linked to adenylyl cyclase inhibition. The existence of a pathway which is not affected by the mutation may be related to the partial response to TXA₂ in these patients.

Discussion

We have shown here that the two isoforms of the human TXA₂ receptor exist in platelets and that these isoforms mediate distinctive spectra of transduction pathways. Although the two isoforms similarly activated PLC, they differently regulated adenylyl cyclase activity; TXR α activated adenylyl cyclase, while TXR β inhibited it. Previous studies using some TXA₂ analogs identified two classes of binding sites in platelets and suggested the possibility that the receptor subtypes corresponding to these two classes are present and mediate separate functional responses of platelets. The presence of the two TXA₂ receptor isoforms in platelets first led us to compare their binding properties in relation to these studies. However, the expression studies in CHO cells and COS cells revealed no difference between the two; both I-BOP and GR32191 displaced specific [³H]S-145 binding to the isoforms similarly, and GR32191 irreversibly bound to both isoforms. These results suggest that the two isoforms do not correspond to the two




Figure 6. Adenylyl cyclase inhibition by wild-type and mutant TXR β . (A and B) I-BOP-induced inhibition of forskolin-induced cAMP accumulation in CHO cells expressing TXR α (●), TXR β (○) or the Arg⁶⁰ to Leu mutant of TXR β (▲). Cells were incubated with 1 μ M forskolin and various concentrations of I-BOP and the cAMP contents were measured. The data are presented as percentages of the control values obtained from the forskolin-stimulated cells in the absence of I-BOP. Data points are mean \pm SE from three replicate wells from a single experiment. The results were independently confirmed in 2 additional experiments. The EC₅₀ values for activation through wild type and Arg⁶⁰ to Leu mutant of TXR β were 0.93 and 4.1 pM, respectively. (C) Effects of pertussis toxin on the I-BOP-induced inhibition of forskolin-induced cAMP accumulation. Cells were cultured in the presence (+) or absence (-) of pertussis toxin (PT) for 12 h, then incubated with 1 μ M forskolin and 100 pM I-BOP and the cAMP contents were determined. Data points are mean \pm SE from six replicate wells from a single experiment. The results were independently confirmed in two additional experiments.

classes of binding sites for some ligands found in intact platelets, unless they behave differently in platelets.

The identification of the pathway linked to adenylyl cyclase inhibition made us to wonder how this pathway is involved in TXA₂-induced platelet responses. Both PLC activation and inhibition of adenylyl cyclase can lead to platelet activation. Given the lower concentrations required for adenylyl cyclase inhibition than for PLC activation, the two pathways might act independently rather than synergistically. We have found that they are distinguished by the effects of the Arg⁶⁰ to Leu mutation; PLC activation is attenuated by this mutation, whereas adenylyl cyclase inhibition is not. This mutation has been identified in a bleeding disorder characterized by defective platelet aggregation responses to TXA₂ and its agonists (13). Previous study demonstrated that despite the impaired activation of PLC, the patients' platelets showed shape change (14) and PLA₂ activation (15), implying the existence of the pathways leading to these responses that are not affected by the mutation. As our studies showed that the inhibition of adenylyl cyclase is unaffected by the mutation, the pathway represented by this parameter might be implicated in shape change and PLA₂ activation. This pathway appears to be mediated by G_i/G_o because it is sensitive to pertussis toxin treatment. This is in accordance with our previous finding that the purified TXA₂ receptor is functionally reconstituted with both G₁₂ and G₁₃ in phospholipid vesicles (29). Consistent with the idea that this G_i/G_o-linked pathway is involved in PLA₂ activation, TXA₂ stimulates mitogen-activated protein kinase via G_i in some types of cells and activates PLA₂ (30, 31). Thus, the present study suggests an intriguing possibility that the TXA₂ receptor isoforms separately mediate different kinds of activation responses in human platelets, although we cannot completely exclude the possibilities that other effector systems linked to the mutated receptor or those mediated by other receptor(s) than the mutated receptor evoke these responses.

Our experiments have also shown stimulation of adenylyl cyclase by one isoform of the TXA₂ receptor. Ishikawa and Ogawa (32) previously found that STA₂ elevated cAMP level in platelets at high concentrations to cause the inhibitory effect on aggregation. Based on this finding, they speculated that this pathway could negatively regulate platelet activation to attenuate or terminate responses. However, the stimulation they observed was not suppressed by a TXA₂ antagonist, ONO-3708. Because ONO-3708 completely displaced the radioligand binding to the cloned TXA₂ receptor (16), it is doubtful that the stimulation observed by these authors is mediated by the TXA₂ receptor we discuss here. Given the fact that stimulation of adenylyl cyclase is observed at relatively high agonist concentrations, the physiological significance of this pathway remains unclear.

Production of multiple isoforms by alternative splicing has been reported in G protein-coupled receptor family (33–38). Two regions of divergence that result from alternative splicing have been identified: the third cytoplasmic loop and the carboxyl-terminal tail. Those that have alternatively-spliced carboxyl tails include several members: the neurokinin-1 receptor (36), the prostaglandin E receptor EP₃ subtype (37), the monocyte chemoattractant protein-1 receptor (38), and the TXA₂ receptor. Alternative splicing of the EP₃ receptor creates isoforms which exhibit distinct functional properties, including different efficiency in activation of a G protein (37), different specificity in coupling to G proteins (39) and different sensitiv-

ity to desensitization (40). The present study suggests that the carboxyl-terminal tails of the two TXA₂ receptor isoforms, like those of the bovine EP₃ receptor (39), determine the specificity of G protein coupling. Furthermore, the distinctive effects of the Arg⁶⁰ to Leu mutation suggested that the interaction of the receptor with different G proteins is distinctly regulated by different domains of the receptor; this residue appears to be important for the interaction of the receptor with G_q and possibly with G_s, but not with G_i/G_o.

Taken together, the data presented here support the existence of multiple signaling pathways via the two TXA₂ receptor isoforms in platelets, which could interact each other to coordinate platelet activation processes. Comparison of the effects of the Arg⁶⁰ to Leu mutation on these pathways with the responses observed in the platelets of the patients with this mutation implicates the possible relationship between the TXRβ-G_i pathway and the platelet shape change and PLA₂ activation. This hypothesis should be rigorously tested in future studies.

Acknowledgments

We thank Ono Pharmaceuticals and Shionogi Company for their kind supply of STA₂ and [³H]S-145, respectively. We also thank R.A. Coleman for kindly providing GR32191.

This work was supported in part by grants-in-aid from the Ministry of Education, Science and Culture and the Ministry of Health and Welfare of Japan, the Japan Society for the Promotion of Science for Young Scientists, the Takeda Science Foundation, the Uehara Memorial Foundation and Funds for Comprehensive Research on Aging and Health.

References

- Kroll, M.H., and A.I. Schafer. 1989. Biochemical mechanisms of platelet activation. *Blood*. 74:1181-1195.
- Samuelson, B., M. Goldyne, E. Granström, M. Hamberg, S. Hammarström, and C. Malmsten. 1978. Prostaglandins and thromboxanes. *Ann. Rev. Biochem.* 47:997-1029.
- Brass, L.F., C.C. Shaller, and E.J. Belmonte. 1987. Inositol 1,4,5-triphosphate-induced granule secretion in platelets: evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin. *J. Clin. Invest.* 79:1269-1275.
- Shenker, A., P. Goldsmith, C.G. Unson, and A.M. Spiegel. 1991. The G protein coupled to the thromboxane A₂ receptor in human platelets is a member of the novel G_q family. *J. Biol. Chem.* 266:9309-9313.
- Johnson, G.J., P.C. Dunlop, L.A. Leis, and H.L. From. 1988. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A₂-prostaglandin H₂ receptor. *Circ. Res.* 62:494-505.
- Morinelli, T.A., S. Niewiarowski, J.L. Daniel, and J.B. Smith. 1987. Receptor-mediated effects of a PGH₂ analogue (U46619) on human platelets. *Am. J. Physiol.* 253:H135-H143.
- Hedberg, A., S.E. Hall, M.L. Ogletree, D.N. Harris, and E.C. Liu. 1988. Characterization of [5, 6-³H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A₂/prostaglandin H₂-receptors in human platelets. *J. Pharmacol. Exp. Ther.* 245:786-792.
- Dorn II, G.W. 1989. Distinct platelet thromboxane A₂/prostaglandin H₂ receptor subtypes. A radioligand binding study of human platelets. *J. Clin. Invest.* 84:1883-1891.
- Dorn II, G.W., and A. DeJesus. 1991. Human platelet aggregation and shape change are coupled to separate thromboxane A₂-prostaglandin H₂ receptors. *Am. J. Physiol.* 260:H327-H334.
- Nakano, T., A. Terawaki, and H. Arita. 1987. Signal transduction in collagen-stimulated rat platelets is composed of three stages. *J. Biochem. (Tokyo)* 101:1169-1180.
- Hanasaki, K., and H. Arita. 1988. Characterization of a new compound, S-145, as a specific TXA₂ receptor antagonist in platelets. *Thromb. Res.* 50:365-376.
- Takahara, K., R. Murray, G.A. FitzGerald, and D.J. Fitzgerald. 1990. The response to thromboxane A₂ analogues in human platelets. Discrimination of two binding sites linked to distinct systems. *J. Biol. Chem.* 265:6836-6844.
- Hirata, T., A. Kakizuka, F. Ushikubi, I. Fuse, M. Okuma, and S. Narumiya. 1994. Arg⁶⁰ to Leu mutation of the human thromboxane A₂ receptor in a dominantly inherited bleeding disorder. *J. Clin. Invest.* 94:1662-1667.
- Ushikubi, F., M. Okuma, K. Kanaji, T. Sugiyama, T. Ogorochi, S. Narumiya, and H. Uchino. 1987. Hemorrhagic thrombocytopeny with platelet thromboxane A₂ abnormality: defective signal transduction with normal binding activity. *Thromb. Haemost.* 57:158-164.
- Fuse, I., M. Mito, A. Hattori, W. Higuchi, A. Shibata, F. Ushikubi, M. Okuma, and K. Yahata. 1993. Defective signal transduction induced by thromboxane A₂ in a patient with a mild bleeding disorder: impaired phospholipase C activation despite normal phospholipase A₂ activation. *Blood*. 81:994-1000.
- Hirata, M., Y. Hayashi, F. Ushikubi, Y. Yokota, R. Kageyama, S. Nakanishi, and S. Narumiya. 1991. Cloning and expression of cDNA for a human thromboxane A₂ receptor. *Nature (Lond.)* 349:617-620.
- Raychowdhury, M.K., M. Yukawa, L.J. Collins, S.H. McGrail, K.C. Kent, and J.A. Ware. 1994. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A₂ receptor. *J. Biol. Chem.* 269:19256-19261 [published erratum appears in *J. Biol. Chem.* 270:7011 (1995)].
- Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156-159.
- Kakizuka, A., W.H. Miller, Jr., K. Umesono, R.P. Warrell, Jr., S.R. Frankel, V.V.V.S. Murty, E. Dmitrovsky, and R.M. Evans. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. *Cell*. 66:663-674.
- Vandenplas, S., I. Wiid, A. Grobler-Rabie, K. Brebner, M. Ricketts, G. Wallis, A. Bester, C. Boyd, and C. Mathew. 1984. Blot hybridization analysis of genomic DNA. *J. Med. Genet.* 21:164-172.
- Nüsing, R.M., M. Hirata, A. Kakizuka, T. Eki, K. Ozawa, and S. Narumiya. 1993. Characterization and chromosomal mapping of the human thromboxane A₂ receptor gene. *J. Biol. Chem.* 268:25253-25259.
- Umesono, K., K.K. Murakami, C.C. Thompson, and R.M. Evans. 1991. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D₃ receptors. *Cell*. 65:1255-1266.
- Graham, F.L., and A.J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. *Virology*. 52:456-467.
- Mizushima, S., and S. Nagata. 1990. pEF-BOS, a powerful mammalian vector. *Nucleic Acids Res.* 18:5322.
- Yokota, Y., Y. Sasai, K. Tanaka, T. Fujiwara, K. Tsuchida, R. Shigemoto, A. Kakizuka, H. Ohkubo, and S. Nakanishi. 1989. Molecular characterization of functional cDNA for rat substance P receptor. *J. Biol. Chem.* 264:17649-17652.
- Ushikubi, F., M. Nakajima, M. Hirata, M. Okuma, F. Fujiwara, and S. Narumiya. 1989. Purification of the thromboxane A₂/prostaglandin H₂ receptor from human blood platelets. *J. Biol. Chem.* 264:16496-16501.
- Berridge, M.J., R.M.C. Dawson, C.P. Downes, J.P. Heslop, and R.F. Irvine. 1983. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. *Biochem. J.* 212:473-482.
- Halushka, P.V., D.E. Mais, P.R. Mayeux, and T.A. Morinelli. 1989. Thromboxane, prostaglandin and leukotriene receptors. *Annu. Rev. Pharmacol. Toxicol.* 10:213-239.
- Ushikubi, F., K. Nakamura, and S. Narumiya. 1994. Functional reconstitution of platelet thromboxane A₂ receptors with G_q and G₁₂ in phospholipid vesicles. *Mol. Pharmacol.* 46:808-816.
- Morinelli, T.A., L. Zhang, W.H. Newman, and K.E. Meier. 1994. Thromboxane A₂/prostaglandin H₂-stimulated mitogenesis of coronary artery smooth muscle cells involves activation of mitogen-activated protein kinase and S6 kinase. *J. Biol. Chem.* 269:5693-5698.
- Lin, L.L., M. Wartmann, A.Y. Lin, J.L. Knopf, A. Seth, and R.J. Davis. 1993. cPLA₂ is phosphorylated and activated by MAP kinase. *Cell*. 72:269-278.
- Ishikawa, Y., and A. Ogawa. 1991. Elevation of platelet cyclic AMP level by thromboxane A₂/prostaglandin H₂ receptor agonists. *Thromb. Res.* 64:667-676.
- Giros, B., P. Sokoloff, M.-P. Martres, J.-F. Riou, L.J. Emorine, and J.-C. Schwarz. 1989. Alternative splicing directs the expression of two D₂ receptor isoforms. *Nature (Lond.)* 342:923-926.
- Monsma, F.J., Jr., L.D. McVittie, C.R. Gerfan, L.C. Mahan, and D.R. Sibley. 1989. Multiple D₂ dopamine receptors produced by alternative RNA splicing. *Nature (Lond.)* 342:926-929.
- Toso, R.D., B. Sommer, M. Ewert, A. Herb, D.B. Pritchett, A. Bach, B.D. Shivers, and P.H. Seeburg. 1989. The dopamine D₂ receptor: two molecular forms generated by alternative splicing. *EMBO J.* 8:4025-4034.
- Fong, T.M., S.A. Anderson, H. Yu, R.-R.C. Huang, and C.D. Strader. 1991. Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. *Mol. Pharmacol.* 41:24-30.
- Sugimoto, Y., M. Negishi, Y. Hayashi, T. Namba, A. Honda, A. Watabe, M. Hirata, S. Narumiya, and A. Ichikawa. 1993. Two isoforms of the EP₃ receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with G_i proteins. *J. Biol. Chem.* 268:2712-2718.
- Charo, I.F., S.J. Myers, A. Herman, C. Franci, A.J. Connolly, and S.R. Coughlin. 1994. Molecular cloning and functional expression of two monocyte

chemoattractant protein-1 receptors reveals alternative splicing of the carboxy-terminal tails. *Proc. Natl. Acad. Sci. USA.* 91:2752–2756.

39. Namba, T., Y. Sugimoto, M. Negishi, A. Irie, F. Ushikubi, A. Kakizuka, S. Ito, A. Ichikawa, and S. Narumiya. 1993. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP₃ determines G-protein specificity.

Nature (Lond.). 365:166–170.

40. Negishi, M., Y. Sugimoto, A. Irie, S. Narumiya, and A. Ichikawa. 1993. Two isoforms of prostaglandin E receptor EP₃ subtype; different COOH-terminal domains determine sensitivity to agonist-induced desensitization. *J. Biol. Chem.* 268:9517–9521.